Australia's most trusted
source of pharma news
Posted 10 July 2024 AM
The Thoracic Society of Australia and New Zealand (TSANZ) has cut ties with Mundipharma and warned a backlash from its members could include deprescribing all the company's products after the pharma entered a new deal with inhaled medicines specialist, Vectura, which is owned by tobacco giant Philip Morris International (PMI).
In April, Mundipharma announced a 'collaboration agreement' with Vectura for the reformulation of its asthma product Flutiform. The decision has caused outrage, with the peak body - which has an 1800 strong membership, more than half of whom are respiratory specialists - taking a stand against the company.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.